PFM Health Sciences’s Sage Therapeutics SAGE Stock Holding History

PFM Health Sciences’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-436,477	Closed	-$12.5M	–	86
2020 Q1	$12.5M	Buy	+436,477	New	+$25.3M	1.03%	37
2019 Q4	–	Sell	-373,828	Closed	-$52.4M	–	75
2019 Q3	$52.4M	Buy	+373,828	New	+$62.5M	1.55%	25
2019 Q2	–	Sell	-169,676	Closed	-$27M	–	98
2019 Q1	$27M	Sell	169,676 -336,100	-66%	-$48.7M	0.6%	57
2018 Q4	$48.4M	Buy	+505,776	New	+$57.9M	1.29%	33
2017 Q2	–	Sell	-75,158	Closed	-$5.34M	–	106
2017 Q1	$5.34M	Buy	+75,158	New	+$4.4M	0.13%	90
2016 Q2	–	Sell	-198,058	Closed	-$6.35M	–	100
2016 Q1	$6.35M	Buy	198,058 +157,208	+385%	+$5.53M	0.2%	74
2015 Q4	$2.38M	Buy	+40,850	New	+$2.02M	0.07%	65

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PFM Health Sciences's SAGE Position: Q2 2020 in Review

PFM Health Sciences sold out of Sage Therapeutics (SAGE) in Q2 2020, closing a stake of 436,477 shares — an estimated $12.5M sold.

PFM Health Sciences first reported a position in SAGE in Q4 2015 and held it in 7 quarters. The position peaked at $52.4M in Q3 2019. 216 funds tracked by Wall St. Rank hold SAGE as of Q2 2020.

PFM Health Sciences reported no remaining Sage Therapeutics position as of Q2 2020 after selling out during the quarter.
PFM Health Sciences sold 436,477 Sage Therapeutics shares in Q2 2020, an estimated $12.5M.
PFM Health Sciences first reported a position in Sage Therapeutics in Q4 2015 and held it in 7 quarters.
PFM Health Sciences's Sage Therapeutics position peaked at $52.4M in Q3 2019.
216 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2020.

Based on PFM Health Sciences's 13F filing for Q2 2020, filed 14 Aug 2020.